Low Risk Prostate Cancer

Clinical trials for patients who are diagnosed with low risk prostate cancer:  Patients with a PSA less than 10, Gleason 6 and cancer involves one half of one side of the prostate or less. (Stage 1)

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT Number: NCT06402331
Phase: PHASE2|PHASE3
Trial Summary: This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym: AlphaBreak

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

NCT Number: NCT06212583
Phase: PHASE2
Trial Summary: The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, Davis
Acronym: KNIGHTS

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study

NCT Number: NCT06125145
Phase: PHASE2
Trial Summary: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and m – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, Davis
Acronym: GAP

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

NCT Number: NCT06437574
Phase: PHASE2
Trial Summary: To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Cedars-Sinai Medical Center
Acronym:

CV CARE: CardioVascular Care in PC Patients

NCT Number: NCT06202820
Phase: NA
Trial Summary: This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:

A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework

NCT Number: NCT06461416
Phase: NA
Trial Summary: Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. – clinicaltrials.gov for more information and locations
* Aim 2: To determine the preliminary effect sizes of ActiveHeal ES – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Arkansas
Acronym:

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

NCT Number: NCT06398639
Phase: EARLY_PHASE1
Trial Summary: The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man’s risk of cancer, together – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Alabama at Birmingham
Acronym: PRS

MRI Guided Prostate Biopsy

NCT Number: NCT06302595
Phase: NA
Trial Summary: This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibi – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Brigham and Women’s Hospital
Acronym:

Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

NCT Number: NCT05948657
Phase:
Trial Summary: This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermedi – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: ESCAPE

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

NCT Number: NCT06051942
Phase: NA
Trial Summary: The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract sym – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): PROCEPT BioRobotics
Acronym:

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT Number: NCT05765500
Phase:
Trial Summary: This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. T – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:

Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)

NCT Number: NCT05882253
Phase:
Trial Summary: The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy. – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): The University of Texas Health Science Center at San Antonio
Acronym: IMAGINED

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

NCT Number: NCT05926102
Phase:
Trial Summary: Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot iden – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym: ProGRESS

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

NCT Number: NCT04300855
Phase: Phase 2
Trial Summary: This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of wh – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Acronym:

Diffusion Basis Spectrum Imaging of the Prostate

NCT Number: NCT04420702
Phase: Not Applicable
Trial Summary: Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically si – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Washington University School of Medicine
Acronym:

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2

NCT Number: NCT04815876
Phase: NA
Trial Summary: Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistanc – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: PREVENT2

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

NCT Number: NCT05424783
Phase: Not Applicable
Trial Summary: The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Northwestern University
Acronym: MAGIC

Stereotactic Ablative Radiation Therapy for Prostate Cancer

NCT Number: NCT05668351
Phase: NA
Trial Summary: This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medical University of South Carolina
Acronym: SUPR-SABR

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NCT Number: NCT04396808
Phase: Not Applicable
Trial Summary: This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC cl – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study

NCT Number: NCT04870515
Phase: Not Applicable
Trial Summary: This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fred Hutchinson Cancer Center
Acronym:

The Genomic Medicine at VA Study

NCT Number: NCT04331535
Phase: Not Applicable
Trial Summary: This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston VA Research Institute, Inc.
Acronym: GenoVA

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT Number: NCT04585750
Phase: Phase 1|Phase 2
Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): PMV Pharmaceuticals, Inc
Acronym:

Video Education With Result Dependent dIsclosure

NCT Number: NCT05225428
Phase: Not Applicable
Trial Summary: The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym: VERDI

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

NCT Number: NCT05471414
Phase: Not Applicable
Trial Summary: The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivatio – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: WFPBD

African Cancer Genome: GMD

NCT Number: NCT05754658
Phase:
Trial Summary: he goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fox Chase Cancer Center
Acronym:

A Study of Mental Health Care in People With Cancer

NCT Number: NCT06037954
Phase: NA
Trial Summary: The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for c – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:

IS-002 in Prostate Cancer

NCT Number: NCT05946603
Phase: PHASE2
Trial Summary: Phase 2 randomized controlled multi-center study of IS-002, in conjunction with near-infrared (NIR) fluorescence imaging, for identification of prostate cancer during robotic-assisted radical prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:

Understanding of Genetics by Men at Risk for Prostate Cancer

NCT Number: NCT04550845
Phase: NA
Trial Summary: With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understand – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:

Contributions to Hypertension With Androgen Deprivation Therapy

NCT Number: NCT05700903
Phase: PHASE4
Trial Summary: This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin can- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: ARCH

Two Fraction Prostate SBRT With DIL SIB

NCT Number: NCT05864196
Phase: PHASE1
Trial Summary: Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NYU Langone Health
Acronym:

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT Number: NCT05915442
Phase: PHASE2
Trial Summary: This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Catherine Spina
Acronym: SBRT-AMICO

Collection of Blood From Patients With Cancer

NCT Number: NCT00034216
Phase:
Trial Summary: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and ol – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

NCT Number: NCT04995198
Patient Summary
Phase:
Trial Summary: PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Prostate Cancer Clinical Trials Consortium
Acronym:

Pre-operative Education Modalities to Decrease Opioid Use

NCT Number: NCT04933084
Phase: NA
Trial Summary: This is a triple-armed, randomized, controlled, non-blinded trial to study the effect of preoperative patient education in conjunction with a limited opioid peri-operative analgesia program on post-op – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Benaroya Research Institute
Acronym:

Optimization of Prostate Biopsy – Micro-Ultrasound Versus MRI

NCT Number: NCT05220501
Phase: NA
Trial Summary: OPTIMUM is a study designed to compare the ability of ultra-high resolution transrectal micro-ultrasound (microUS) and multiparametric MRI (mpMRI)/US fusion to guide prostate biopsy. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sunnybrook Health Sciences Centre
Acronym: OPTIMUM

Clinical Trial of Approaches to Prostate Cancer Surgery

NCT Number: NCT05155501
Phase: NA
Trial Summary: This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatect – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: PARTIAL

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

NCT Number: NCT05710380
Phase: NA
Trial Summary: Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

NCT Number: NCT04573231
Phase: PHASE2
Trial Summary: The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive me – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:

Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

NCT Number: NCT05519878
Phase: Not Applicable
Trial Summary: This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers. Light therapy is a non-pharmacological and evidence- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym:

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

NCT Number: NCT05804318
Phase: Not Applicable
Trial Summary: This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Varian, a Siemens Healthineers Company
Acronym: ARTIA-Prostate

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

NCT Number: NCT05826470
Phase: NA
Trial Summary: Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer. FLA has been extensively utilized – clinicaltrials.gov for more
Clinicaltrials.gov
Trial Sponsor(s): Genesis Research LLC
Acronym:

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

NCT Number: NCT05751434
Phase: Phase 2
Trial Summary: The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. Th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT Number: NCT05629494
Phase: Phase 4
Trial Summary: Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and ele – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Albany Medical College
Acronym: ADAPT-PSA

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

NCT Number: NCT05597878
Phase: Phase 2|Phase 3
Trial Summary: The objective of this study is to conduct a randomized clinical trial to evaluate an opioid versus an opioid-free pathway of perioperative use of ketamine, ketorolac, and IV acetam – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Wake Forest University Health Sciences
Acronym:

Improving Germline Testing in At-Risk Patients With Prostate Cancer

NCT Number: NCT05470036
Phase: Not Applicable
Trial Summary: A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational sessi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym: IMPRINT

UroLift System With SAbR for Prostate Cancer and BPH

NCT Number: NCT05311527
Phase: PHASE1
Trial Summary: Confirming safety of combining UroLift System prior to SAbR for patients with newly diagnosed prostate cancer and a history of BPH, by measuring the acute complication rate of UroL – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Texas Southwestern Medical Center
Acronym:

Social Risk Factors and Discrimination in Cancer Survivorship

NCT Number: NCT05301114
Phase: NA
Trial Summary: The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medstar Health Research Institute
Acronym:

Methods for Increasing Genetic Testing Uptake in Michigan

NCT Number: NCT05162846
Phase: NA
Trial Summary: The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym: MiGHT

Improving Care After Inherited Cancer Testing

NCT Number: NCT04763915
Phase: NA
Trial Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genet – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Vanderbilt-Ingram Cancer Center
Acronym: IMPACT

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT Number: NCT04692675
Phase: Not Applicable
Trial Summary: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored. AS uses biopsies, prostate specific an – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

Researching the Effect of Exercise on Cancer

NCT Number: NCT04589468
Phase: NA
Trial Summary: Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

NCT Number: NCT04597359
Phase: Phase 2
Trial Summary: This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surv – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Acronym:

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

NCT Number: NCT04530552
Phase: Phase 2
Trial Summary: This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT Number: NCT04373564
Phase: PHASE4
Trial Summary: This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detaile – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Guerbet
Acronym: ODYSSEY

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

NCT Number: NCT04253483
Phase: Phase 2
Trial Summary: This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to oth – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI)
Acronym:

Onco-primary Care Networking to Support TEAM-based Care

NCT Number: NCT04258813
Phase: NA
Trial Summary: The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Duke University
Acronym: ONE TEAM

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

NCT Number: NCT03880422
Phase: Not Applicable
Trial Summary: This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym:

CyberKnife Dose Escalation Prostate Cancer Trial

NCT Number: NCT03822494
Phase: Not Applicable
Trial Summary: Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates wit – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Crozer-Keystone Health System
Acronym: CK-DESPOT

Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer

NCT Number: NCT02334579
Phase: Not Applicable
Trial Summary: The purpose of this study is to find out the effects (good and bad) of highly focused radiation on you and your prostate cancer. The purpose of this evaluation is to see if this tr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Swedish Medical Center
Acronym:

Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors

NCT Number: NCT02600156
Phase: Not Applicable
Trial Summary: The primary purpose of this study is to evaluate the feasibility and safety of MRI-guided focal laser ablation (Laser-Induced Interstitial Thermal Therapy, LITT) to treat low-risk – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym:

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

NCT Number: NCT02016248
Phase: Not Applicable
Trial Summary: The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKn – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MemorialCare Health System
Acronym:

MRI for Assessing Prostate Cancer Response

NCT Number: NCT01607008
Phase: Not Applicable
Trial Summary: Prostate cancer is one of most common cancers in America, affecting 1 in 6 men. External beam radiation therapy is one of the common methods to treat prostate cancer. Although radi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym: NA_00067284

Find Your Trial

Low Risk

Intermediate Risk

High Risk

Cancer Recurrence

Non-Metastatic Castration Resistant

Metastatic Castration Sensitive

Metastatic Castration Resistant

Promise Registry - All Risk Levels

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations by screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes.

Pin It on Pinterest